Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

ADAMTS13 exerts a thrombolytic effect in microcirculation.

Crescente M, Thomas GM, Demers M, Voorhees JR, Wong SL, Ho-Tin-Noé B, Wagner DD.

Thromb Haemost. 2012 Sep;108(3):527-32. doi: 10.1160/TH12-01-0046. Epub 2012 Jul 10.

2.

The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy.

Boulaftali Y, Lamrani L, Rouzaud MC, Loyau S, Jandrot-Perrus M, Bouton MC, Ho-Tin-Noé B.

Thromb Haemost. 2012 May;107(5):962-71. doi: 10.1160/TH11-10-0705. Epub 2012 Mar 8.

3.

Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice.

Wang L, Fan W, Cai P, Fan M, Zhu X, Dai Y, Sun C, Cheng Y, Zheng P, Zhao BQ.

Ann Neurol. 2013 Feb;73(2):189-98. doi: 10.1002/ana.23762. Epub 2012 Dec 31.

PMID:
23280993
4.

Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.

Nakano T, Irie K, Hayakawa K, Sano K, Nakamura Y, Tanaka M, Yamashita Y, Satho T, Fujioka M, Muroi C, Matsuo K, Ishikura H, Futagami K, Mishima K.

Brain Res. 2015 Oct 22;1624:330-5. doi: 10.1016/j.brainres.2015.07.027. Epub 2015 Aug 5.

PMID:
26254727
5.

Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.

Leadley RJ Jr, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.

Thromb Haemost. 1997 Oct;78(4):1278-85.

PMID:
9364998
6.

A novel hollow and perforated flexible wire allows the safe and effective local application of thrombolytic therapy in a mouse model of deep vein thrombosis.

Witsch T, Mauler M, Herr N, Stallmann D, Bode C, Hehrlein C, Duerschmied D.

J Thromb Thrombolysis. 2014 May;37(4):450-4. doi: 10.1007/s11239-013-1013-x.

PMID:
24163054
7.

ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice.

Denorme F, Langhauser F, Desender L, Vandenbulcke A, Rottensteiner H, Plaimauer B, François O, Andersson T, Deckmyn H, Scheiflinger F, Kleinschnitz C, Vanhoorelbeke K, De Meyer SF.

Blood. 2016 May 12;127(19):2337-45. doi: 10.1182/blood-2015-08-662650. Epub 2016 Feb 29.

8.

Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis.

Xiao J, Jin SY, Xue J, Sorvillo N, Voorberg J, Zheng XL.

Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2261-9. doi: 10.1161/ATVBAHA.111.229609. Epub 2011 Jul 28.

9.

Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.

Tersteeg C, de Maat S, De Meyer SF, Smeets MW, Barendrecht AD, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot PG, Maas C.

Circulation. 2014 Mar 25;129(12):1320-31. doi: 10.1161/CIRCULATIONAHA.113.006727. Epub 2014 Jan 21.

10.

von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.

Zhao BQ, Chauhan AK, Canault M, Patten IS, Yang JJ, Dockal M, Scheiflinger F, Wagner DD.

Blood. 2009 Oct 8;114(15):3329-34. doi: 10.1182/blood-2009-03-213264. Epub 2009 Aug 17.

12.

Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.

Wang X, Smith PL, Hsu MY, Ogletree ML, Schumacher WA.

J Thromb Haemost. 2006 Feb;4(2):403-10.

13.

Systemic antithrombotic effects of ADAMTS13.

Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, Scheiflinger F, Ginsburg D, Wagner DD.

J Exp Med. 2006 Mar 20;203(3):767-76. Epub 2006 Mar 13.

14.

Comparison of retavase and urokinase for management of spontaneous subclavian vein thrombosis.

Gelabert HA, Jimenez JC, Rigberg DA.

Ann Vasc Surg. 2007 Mar;21(2):149-54.

PMID:
17349354
15.

Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W.

Pruss CM, Golder M, Bryant A, Hegadorn C, Haberichter S, Lillicrap D.

J Thromb Haemost. 2012 May;10(5):940-50. doi: 10.1111/j.1538-7836.2012.04675.x.

16.
17.
18.

Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.

McCarthy JR, Sazonova IY, Erdem SS, Hara T, Thompson BD, Patel P, Botnaru I, Lin CP, Reed GL, Weissleder R, Jaffer FA.

Nanomedicine (Lond). 2012 Jul;7(7):1017-28. doi: 10.2217/nnm.11.179. Epub 2012 Feb 21.

19.

New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.

Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, Bennett WF.

Circulation. 1995 Nov 15;92(10):3032-40.

20.

Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner.

Bao J, Xiao J, Mao Y, Zheng XL.

Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):397-407. doi: 10.1161/ATVBAHA.113.302547. Epub 2013 Dec 19.

Supplemental Content

Support Center